title: Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms.
abstract: Recently a new effervescent acetylsalicylic acid (ASA) tablet with high buffering capacity has been developed. In this double-blind, 3-arm, multicenter, parallel-group study, 433 patients were treated either with 1,000 mg effervescent ASA or 50 mg encapsulated sumatriptan or placebo. The primary endpoint was the percentage of patients with complete remission of the 3 accompanying symptoms nausea, photophobia and phonophobia within 2 h after intake of the study drug. 43.8% of patients treated with ASA, 43.7% of patients treated with sumatriptan and 30.9% of patients treated with placebo showed complete remission of all 3 accompanying symptoms (p < 0.05 for ASA and sumatriptan vs. placebo). Both active treatments were superior to placebo regarding the individual symptoms photophobia and phonophobia, but not for nausea. The percentage of patients with reduction in headache severity from moderate or severe to mild or no pain (secondary objective) was 49.3% for ASA, 48.8% for sumatriptan and 32.9% for placebo. All active treatments were superior to placebo (p < 0.05). 25.3, 24.4 and 14.5% of patients treated with ASA, sumatriptan or placebo were pain free at 2 h. Drug-related adverse events were reported in 3.9, 4.7 and 6.7% of patients treated with placebo, ASA or sumatriptan. The study showed that administration of effervescent ASA leads to remission of the migraine symptoms nausea, photophobia and phonophobia, reduces migraine headache and is comparable to sumatriptan.
authors.affiliation: Department of Neurology, University of Essen, Hufelandstrasse 55, DE-45147 Essen, Germany. h.diener@uni-essen.de
authors.forename: H C
authors.initials: HC
authors.lastname: Diener
authors.forename: A
authors.initials: A
authors.lastname: Eikermann
authors.forename: U
authors.initials: U
authors.lastname: Gessner
authors.forename: H
authors.initials: H
authors.lastname: Göbel
authors.forename: G
authors.initials: G
authors.lastname: Haag
authors.forename: R
authors.initials: R
authors.lastname: Lange
authors.forename: A
authors.initials: A
authors.lastname: May
authors.forename: G
authors.initials: G
authors.lastname: Müller-Schwefe
authors.forename: M
authors.initials: M
authors.lastname: Voelker
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001241:Aspirin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D003710:Demography; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D018170:Sumatriptan / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
chemical_list: D014662:Vasoconstrictor Agents; D018170:Sumatriptan; D001241:Aspirin; C006387:acetylsalicylsalicylic acid